Clovertex’s October Target of the Month is human serum albumin, the body’s most abundant circulating...
Clovertex’s September 2025 Target of the Month is LGR5, in light of Genmab’s announcement that it wi...
Clovertex’s August 2025 Target of the Month is MC4R (melanocortin‑4 receptor). MC4R is a GPCR that p...
Clovertex’s June Target of the Month is KIT, highlighted by Sanofi’s acquisition of Blueprint Medici...
Clovertex’s May Target of the Month is B-Raf, a serine/threonine kinase that plays a central role in...
Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S. FD...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
Clovertex's February Target of the Month is the farnesoid X receptor (FXR), a nuclear receptor that ...
Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & John...
Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has...